Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment (Englisch)
- Neue Suche nach: Volokhina, E
- Neue Suche nach: Wijnsma, K
- Neue Suche nach: van der Molen, R
- Neue Suche nach: Roeleveld, N
- Neue Suche nach: van der Velden, T
- Neue Suche nach: Goertz, J
- Neue Suche nach: Sweep, F
- Neue Suche nach: Brüggemann, RJ
- Neue Suche nach: Wetzels, J
- Neue Suche nach: van de Kar, N
- Neue Suche nach: van den Heuvel, L
- Neue Suche nach: Volokhina, E
- Neue Suche nach: Wijnsma, K
- Neue Suche nach: van der Molen, R
- Neue Suche nach: Roeleveld, N
- Neue Suche nach: van der Velden, T
- Neue Suche nach: Goertz, J
- Neue Suche nach: Sweep, F
- Neue Suche nach: Brüggemann, RJ
- Neue Suche nach: Wetzels, J
- Neue Suche nach: van de Kar, N
- Neue Suche nach: van den Heuvel, L
In:
Clinical Pharmacology & Therapeutics
;
102
, 4
;
671-678
;
2017
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment
-
Beteiligte:Volokhina, E ( Autor:in ) / Wijnsma, K ( Autor:in ) / van der Molen, R ( Autor:in ) / Roeleveld, N ( Autor:in ) / van der Velden, T ( Autor:in ) / Goertz, J ( Autor:in ) / Sweep, F ( Autor:in ) / Brüggemann, RJ ( Autor:in ) / Wetzels, J ( Autor:in ) / van de Kar, N ( Autor:in )
-
Erschienen in:Clinical Pharmacology & Therapeutics ; 102, 4 ; 671-678
-
Verlag:
-
Erscheinungsdatum:01.10.2017
-
Format / Umfang:8 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Englisch
-
Datenquelle:
Inhaltsverzeichnis – Band 102, Ausgabe 4
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 555
-
Issue Information| 2017
- 563
-
In This Issue| 2017
- 564
-
Inflammation: Treatment Progress and LimitationsCascorbi, Ingolf et al. | 2017
- 568
-
Highlights| 2017
- 570
-
ASCPT NEWS| 2017
- 574
-
Is There a Renaissance of Glucocorticoids in Rheumatoid Arthritis?Kirwan, JR / Gunasekera, WMA et al. | 2017
- 578
-
Utilizing PBPK Modeling to Evaluate the Potential of a Significant Drug–Drug Interaction Between Clopidogrel and Dasabuvir: A Scientific PerspectiveArya, V / Zhao, P / Reynolds, KS / Mishra, P / Younis, IR et al. | 2017
- 580
-
Psilocybin: Good Trip or Bad TripSellers, EM et al. | 2017
- 585
-
Value of Biomarkers in the Prevention of Rheumatoid ArthritisFinckh, A / Alpizar‐Rodriguez, D / Roux‐Lombard, P et al. | 2017
- 588
-
Fecal Microbial Transplantation in Inflammatory Bowel Disease: A Movement Too Big to Be IgnoredLaffin, M / Madsen, KL et al. | 2017
- 591
-
The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in InflammationRose‐John, Stefan et al. | 2017
- 599
-
Cancer‐Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized MedicineShinko, Diana / Diakos, Connie I. / Clarke, Stephen J. / Charles, Kellie A. et al. | 2017
- 611
-
Cyclooxygenase Inhibition: Pain, Inflammation, and the Cardiovascular SystemGrosser, Tilo / Theken, Katherine N. / FitzGerald, Garret A. et al. | 2017
- 623
-
Precision Medicine in Inflammatory Bowel DiseasesFischer, Sarah / Neurath, Markus F. et al. | 2017
- 633
-
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel DiseaseHindryckx, Pieter / Novak, Gregor / Bonovas, Stefanos / Peyrin‐Biroulet, Laurent / Danese, Silvio et al. | 2017
- 642
-
Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical ChecklistYiu, Zenas Z.N. / Warren, Richard B. et al. | 2017
- 649
-
Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and VictimsCavaco, M / Goncalves, J et al. | 2017
- 662
-
Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme ActivityNie, Q / Shrestha, S / Tapper, EE / Trogstad‐Isaacson, CS / Bouchonville, KJ / Lee, AM / Wu, R / Jerde, CR / Wang, Z / Kubica, PA et al. | 2017
- 671
-
Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized TreatmentVolokhina, E / Wijnsma, K / van der Molen, R / Roeleveld, N / van der Velden, T / Goertz, J / Sweep, F / Brüggemann, RJ / Wetzels, J / van de Kar, N et al. | 2017
- 679
-
Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and DasabuvirShebley, M / Fu, W / Badri, P / Bow, DAJ / Fischer, V et al. | 2017
- 688
-
Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing ProjectsZhou, Y / Ingelman‐Sundberg, M / Lauschke, VM et al. | 2017
- 701
-
Ethnic Difference in the Pharmacodynamics‐efficacy Relationship of Dipeptidyl Peptidase‐4 Inhibitors Between Japanese and non‐Japanese Patients: A Systematic ReviewIto, Y / Ambe, K / Kobayashi, M / Tohkin, M et al. | 2017
- 709
-
Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune‐mediated NeuropathiesFokkink, WJR / Koch, BCP / Ramakers, CRB / van Doorn, PA / van Gelder, T / Jacobs, BC et al. | 2017